Evidence map›Paper›PMID 32807964›Full record

ArticleNature chemical biology2020

Targeted glycan degradation potentiates the anticancer immune response in vivo.

Melissa A Gray, Michal A Stanczak, Natália R Mantuano, Han Xiao, Johan F A Pijnenborg, Stacy A Malaker, Caitlyn L Miller, Payton A Weidenbacher, Julia T Tanzo, Green Ahn and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers.

0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

190 citing papers in PubMed, 343 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Engineering CAR-T cells to remodel the mucin-rich cancer cell glycocalyx.bioRxiv : the preprint server for biology · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Spatial Glyco-Codes Define Human Liver Pathology and Progression.bioRxiv : the preprint server for biology · 2026
    Article
  18. Review
  19. Article
  20. Review

130 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Melissa A GrayDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Michal A StanczakCancer Immunology Laboratory, Department of Biomedicine, University Hospital, Basel, Switzerland.
Natália R MantuanoCancer Immunology Laboratory, Department of Biomedicine, University Hospital, Basel, Switzerland.
Han XiaoDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Johan F A PijnenborgDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Stacy A MalakerDepartment of Chemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2382-5067
Caitlyn L MillerDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5120-7149
Payton A WeidenbacherDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Julia T TanzoDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Green AhnDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Elliot C WoodsDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Heinz LäubliCancer Immunology Laboratory, Department of Biomedicine, University Hospital, Basel, Switzerland.ORCID http://orcid.org/0000-0002-8910-5620
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, USA. bertozzi@stanford.edu.ORCID http://orcid.org/0000-0003-4482-2754
Stanford University · USUniversity Hospital of Basel · CHHoward Hughes Medical Institute · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI · 2007 to 2026
$71.4M
Targeting the Cancer GlycocalyxR01CA227942 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2019 to 2026
$3.6M
Stanford Chem-H Chemistry/Biology Interface Predoctoral Training ProgramT32GM120007 · NIGMS · STANFORD UNIVERSITY · PI BERTOZZI, CAROLYN · 2016 to 2020
$1.2M
Development of Mucin-mimetics to Study the Role of the Glycocalyx in OncogenesisF31CA200544 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI WOODS, ELLIOT CARTER · 2015 to 2016
$74k
Howard Hughes Medical InstituteNCI NIH HHS F31 CA200544NCI NIH HHS R01 CA227942NIGMS NIH HHS T32 GM120007
6 · The paper itself

Abstract

Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4 receptor pathways are powerful treatment options for certain cancers; however, most patients across cancer types still fail to respond. Consequently, there is interest in discovering and blocking alternative pathways that mediate immune suppression. One such mechanism is an upregulation of sialoglycans in malignancy, which has been recently shown to inhibit immune cell activation through multiple mechanisms and therefore represents a targetable glycoimmune checkpoint. Since these glycans are not canonically druggable, we designed an αHER2 antibody-sialidase conjugate that potently and selectively strips diverse sialoglycans from breast cancer cells. In syngeneic breast cancer models, desialylation enhanced immune cell infiltration and activation and prolonged the survival of mice, an effect that was dependent on expression of the Siglec-E checkpoint receptor found on tumor-infiltrating myeloid cells. Thus, antibody-sialidase conjugates represent a promising modality for glycoimmune checkpoint therapy.

Indexed as

AllograftsAnimalsAntibodies, MonoclonalB7-H1 AntigenCell Line, TumorErb-b2 Receptor Tyrosine KinasesHumansHydrolysisImmunoconjugatesImmunotherapyKiller Cells, NaturalMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutModels, MolecularAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesNeuraminidasePDCD1 protein, humanPolysaccharidesProgrammed Cell Death 1 ReceptorSialic Acid Binding Immunoglobulin-like Lectins

Identifiers

PMID32807964
PMCPMC7727925
OpenAlexW3048973619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.